PureTech Health (0VQ) Stock Overview
Engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
0VQ Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
PureTech Health plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£1.44 |
| 52 Week High | UK£1.59 |
| 52 Week Low | UK£1.18 |
| Beta | 0.79 |
| 1 Month Change | 9.09% |
| 3 Month Change | -8.28% |
| 1 Year Change | -7.10% |
| 3 Year Change | -38.46% |
| 5 Year Change | -61.90% |
| Change since IPO | -53.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0VQ | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.1% | 0.8% | 1.0% |
| 1Y | -7.1% | 8.0% | 3.2% |
Return vs Industry: 0VQ underperformed the German Biotechs industry which returned 8% over the past year.
Return vs Market: 0VQ underperformed the German Market which returned 3.2% over the past year.
Price Volatility
| 0VQ volatility | |
|---|---|
| 0VQ Average Weekly Movement | 6.8% |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 0VQ has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 0VQ's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 90 | Rob Lyne | www.puretechhealth.com |
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, a Phase 3-ready therapeutic candidate with the potential to establish a new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases and LYT-200, a fully human IgG4 monoclonal antibody. The company also develops SPT-300, a Glyphed oral prodrug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions.
PureTech Health plc Fundamentals Summary
| 0VQ fundamental statistics | |
|---|---|
| Market cap | €338.34m |
| Earnings (TTM) | -€95.14m |
| Revenue (TTM) | €4.04m |
Is 0VQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0VQ income statement (TTM) | |
|---|---|
| Revenue | US$4.66m |
| Cost of Revenue | US$56.46m |
| Gross Profit | -US$51.80m |
| Other Expenses | US$57.94m |
| Earnings | -US$109.74m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.45 |
| Gross Margin | -1,111.74% |
| Net Profit Margin | -2,355.42% |
| Debt/Equity Ratio | 61.7% |
How did 0VQ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/03 15:59 |
| End of Day Share Price | 2026/07/31 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PureTech Health plc is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jens Lindqvist | Investec Bank plc (UK) |
| Peter Welford | Jefferies LLC |
| Miles Dixon | Peel Hunt LLP |